venBio, Foresite Capital and Decheng Capital led a $111m Series B round in ImmPact Bio.

venBio, a life sciences investment firm, Foresite Capital, an American venture capital and growth equity firm, and Decheng Capital, an investment company, led a $111m Series B round in ImmPact Bio, a biotechnology company, with participation from OrbiMed, Surveyor Capital and Novartis Venture Fund. "We believe ImmPACT Bio's technology platforms will help to expand the curative potential of cell therapies in certain cancers and to address challenges that have limited the efficacy of cell therapies in hard-to-treat tumor types. We are excited to work with the scientists and clinicians at ImmPACT Bio to translate their engineering innovations into novel cell therapy products for multiple malignancies," Richard Gaste, venBio Partners Managing Partner.